Literature DB >> 31750991

Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents.

Mariane Le Fur1, Nicholas J Rotile1, Carlos Correcher2, Veronica Clavijo Jordan1, Alana W Ross1, Ciprian Catana1, Peter Caravan1.   

Abstract

Gadolinium-based contrast agents (GBCAs) are used to provide diagnostic information in clinical magnetic resonance (MR) examinations. Gadolinium (Gd) has been detected in the brain, bone and skin of patients, months and years following GBCA administration, raising concerns about long term toxicity. Despite increased scrutiny, the concentration, chemical form and fate of the retained gadolinium species remain unknown. Importantly, the whole body biodistribution and organ clearance of GBCAs is poorly understood in humans. Gadolinium lacks suitable isotopes for nuclear imaging. We demonstrate that the yttrium-86 isotope can be used as a gadolinium surrogate. We show that Gd and their analogous Y complexes have similar properties both in solution and in vivo, and that yttrium-86 PET can be used to track the biodistribution of GBCAs over a two-day period.
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  gadolinium retention; imaging agents; magnetic resonance imaging; positron emission tomography; yttrium

Mesh:

Substances:

Year:  2019        PMID: 31750991      PMCID: PMC7027945          DOI: 10.1002/anie.201911858

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  24 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  PET imaging with the non-pure positron emitters: (55)Co, (86)Y and (124)I.

Authors:  P E N Braad; S B Hansen; H Thisgaard; P F Høilund-Carlsen
Journal:  Phys Med Biol       Date:  2015-04-09       Impact factor: 3.609

4.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

Review 5.  Gadolinium deposition in nephrogenic fibrosing dermopathy.

Authors:  Alan S Boyd; John A Zic; Jerrold L Abraham
Journal:  J Am Acad Dermatol       Date:  2006-11-15       Impact factor: 11.527

6.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

7.  Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS.

Authors:  Juliette Moreau; Emmanuel Guillon; Jean-Claude Pierrard; Jean Rimbault; Marc Port; Michel Aplincourt
Journal:  Chemistry       Date:  2004-10-11       Impact factor: 5.236

8.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.

Authors:  Tomonori Kanda; Kazunari Ishii; Hiroki Kawaguchi; Kazuhiro Kitajima; Daisuke Takenaka
Journal:  Radiology       Date:  2013-12-07       Impact factor: 11.105

Review 9.  Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo?

Authors:  James E Huckle; Ersan Altun; Michael Jay; Richard C Semelka
Journal:  Invest Radiol       Date:  2016-04       Impact factor: 6.016

10.  Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.

Authors:  M F Tweedle; P Wedeking; K Kumar
Journal:  Invest Radiol       Date:  1995-06       Impact factor: 6.016

View more
  5 in total

Review 1.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

2.  Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A.

Authors:  Iris Yuwen Zhou; Ian A Ramsay; Ilknur Ay; Pamela Pantazopoulos; Nicholas J Rotile; Alison Wong; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2021-04-01       Impact factor: 10.065

3.  Versatile Macrocyclic Platform for the Complexation of [natY/90Y]Yttrium and Lanthanide Ions.

Authors:  Charlene Harriswangler; Laura Caneda-Martínez; Olivier Rousseaux; David Esteban-Gómez; Olivier Fougère; Rosa Pujales-Paradela; Laura Valencia; M Isabel Fernández; Nicolas Lepareur; Carlos Platas-Iglesias
Journal:  Inorg Chem       Date:  2022-04-14       Impact factor: 5.436

4.  The value of noncontrast MRI in evaluating breast imaging reporting and data system category 0 lesions on digital mammograms.

Authors:  Ruixin Zhang; Maosheng Xu; Changyu Zhou; Xuewei Ding; Huan Lu; Min Ge; Liang Du; Yangyang Bu
Journal:  Quant Imaging Med Surg       Date:  2022-08

5.  Hemoglobin-mediated biomimetic synthesis of paramagnetic O2-evolving theranostic nanoprobes for MR imaging-guided enhanced photodynamic therapy of tumor.

Authors:  Xiudong Shi; Weitao Yang; Qiong Ma; Yang Lu; Yan Xu; Kexin Bian; Fengjun Liu; Chunzi Shi; Han Wang; Yuxin Shi; Bingbo Zhang
Journal:  Theranostics       Date:  2020-09-19       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.